stockrow
Saturday 7 November 2026
Export OBX’s income statement to Excel — free account
Obsidian Therapeutics, Inc
14.02
4.42
+46.04%
Follow OBX
Alert me
| Dec '24 | Dec '25 | |
|---|---|---|
Current Ratio |
10.75 | 5.31 |
Net Debt/EBITDA |
1.88 | 0.77 |
Debt/Assets |
0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 |
Asset Turnover |
— | 0.00 |
Operating CF/Net income |
0.90 | 0.90 |
Capex/Depreciation |
(0.51) | (0.05) |
| 0.00% | 45.68% | |
| 0.00% | (73.90%) | |
ROIC |
0.00% | 0.00% |
Return on Tangible Assets |
(51.92%) | (147.81%) |
Research and Development Expense of Revenue |
0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% |
Free Cash Flow per Share |
(5.90) | (6.49) |
Cash per Share |
13.10 | 5.78 |
Shareholders Equity per Share |
(13.58) | (19.09) |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
(13.58) | (19.09) |
Free Cash Flow |
(75.78) | (90.47) |
Working Capital |
156.76 | 66.15 |
Capital Expenditures |
(0.78) | (0.07) |
Net Current Asset Value |
(185.30) | (273.10) |
| Other line items | ||
Quick Ratio |
10.46 | 5.24 |
Depreciation/Fixed assets |
0.46 | 0.78 |
Cash ROIC |
1,230.01% | 48.76% |
Accounts Payable Turnover |
— | 0.00 |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(5.84) | (6.49) |
Capex per Share |
(0.06) | (0.01) |
Average Payables |
— | 0.92 |
Average Assets |
— | 136.15 |
Average Common Equity |
— | (220.23) |
Capex to Sales |
0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026